Skip to content

Role of platelet rich plasma and prolotherapy in pain of patients with knee osteoarthritis

A comparative study between platelet rich plasma and prolotherapy for pain relief in patients of knee osteoarthritis

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/11/038195
Enrollment
64
Registered
2021-11-23
Start date
Unknown
Completion date
Unknown
Last updated
2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: S818- Open wound of lower leg

Interventions

Intervention1: Autologous platelets rich plasma: autologous PRP from the department of Transfusion Medicine, KGMU, Lucknow from autologous donor Control Intervention1: Prolotherapy (25% dextrose solut

Sponsors

King Georges Medical University
Lead Sponsor
Department of Transfusion Medicine
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Patients giving written consent will be taken, Patient in the age group of 40 to 70 years. Knee osteoarthritis grade I & II (According to Kellgren et al classification scale)

Exclusion criteria

Exclusion criteria: Patients not giving informed consent, Knee osteoarthritis grade III to IV (According to Kellgren et al classification scale), Patients with rheumatoid arthritis or hemophilia, previous history of knee surgery, drug or alcohol addiction, and use of anticoagulant or nonsteroidal anti-inflammatory drugs (NSAIDS) in previous 7 days.

Design outcomes

Secondary

MeasureTime frame
ï?§ Followup will be done through OPD visits and regular mobile communication to ask regarding pain relief until 24 week and grading pain relief with respect to VAS and WOMAC scoreTimepoint: 24 week and grading pain

Primary

MeasureTime frame
ï?§ After injection patient will be offered acetaminophen tablets to use as needed for up to 1 week and advise knee rest for 2 -4 days with progressive resumption of routine activity over 1 month ï?§ They will be discouraged from using NSAIDS and start new therapies for their OA during study period Timepoint: VAS & WOMAC Score at 1 week, 1month, 3months & 6months.

Countries

India

Contacts

Public ContactProf Sarita Singh

King Georges Medical University Lucknow

satyendrab786@gmail.com9532615781

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026